Epidemiologic approach to open-angle glaucoma: 2. Survival analysis of adverse drug reactions. Report of the Canadian Ocular Adverse Drug Reaction Registry Program. The Collaborative Glaucoma Study Group.
Medical treatment, intraocular pressure (IOP) and adverse drug reactions were recorded in a prospective multicentre study of 71 unselected, newly diagnosed cases of open-angle glaucoma. Eight ophthalmologists recorded standard information at five visits over a mean interval of 12.1 months. No limitations were imposed on the choice of drugs or interval between visits. The IOP was satisfactorily controlled throughout the follow-up period with the first drug prescribed in 36% of eyes. In an additional 10% to 13% the IOP was stabilized with alternative therapy, prescribed for approximately one-third of eyes per visit. A total of 27 patients reported 18 severe and 31 mild suspected adverse reactions during the follow-up period. Survival analysis showed that there was no significant difference between the proportions of patients continuing treatment with the first, second and third drug prescribed (half-life of treatment approximately 210 days in all three cases). However, when only changes for unsatisfactory pressure were considered, the half-life of treatment was significantly longer, 350 days (p = 0.02).
Begg
I S
IS
Department of Ophthalmology, University of British Columbia, Vancouver.
Cottle
R W
RW
D000086:Acetazolamide / Q000009:adverse effects; D000328:Adult; D000367:Age Factors; D000368:Aged; D004837:Epinephrine / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D010862:Pilocarpine / Q000009:adverse effects; D013997:Time Factors; D013999:Timolol / Q000009:adverse effects
D009883:Ophthalmic Solutions; D010862:Pilocarpine; D013999:Timolol; C015173:dipivefrin; C018285:epinephryl borate; D000086:Acetazolamide; D004837:Epinephrine